Urogenital rhabdomyosarcoma in childhood.
Recent advances in chemotherapy and radiotherapy have improved the prognosis of urogenital rhabdomyosarcoma. Preliminary reports suggest that a mutilative operation may no longer be essential to cure this disease.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D003609:Dactinomycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000628:therapy; D012208:Rhabdomyosarcoma / Q000628:therapy*; D013736:Testicular Neoplasms / Q000628:therapy; D014523:Urethral Neoplasms / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014565:Urogenital Neoplasms / Q000628:therapy*; D014625:Vaginal Neoplasms / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine